ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
17.952,12
0,26%
S&P 500
5.064,20
0,91%
Dow Jones
38.225,66
0,85%
Euro vs US Dollar
1,07256
-0,04%
Bitcoin
59.213,51
0,16%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Addex Therapeutics Ltd (ADXN)

  7. Addex Therapeutics Ltd (ADXN) News

ADXN Addex Therapeutics Ltd

8,85
0,00 (0,00%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Addex Therapeutics Ltd ADXN NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 8,85 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
8,85
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
29.4.202407:00GLOBEAddex Provides Update on ADX71149 Phase 2 Epilepsy Study
19.4.202407:00GLOBEAddex to Present at the Swiss Biotech Day 2024
18.4.202407:00GLOBEAddex Therapeutics Reports Full Year 2023 Financial Results..
11.4.202407:00GLOBEAddex Therapeutics to Release Full-Year 2023 Financial..
03.4.202407:00GLOBEAddex and Perceptive Launch Neurosterix with $63 Million to..
14.3.202407:00GLOBEAddex to Present at the Bio-Europe Spring 2024 Conference
31.1.202407:00GLOBEAddex Enters into At-The-Market ADS Offering Agreement with..
30.1.202423:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30.1.202422:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09.1.202407:00GLOBEAddex to Present at the Swiss Equities Baader Conference
05.1.202407:30GLOBEAddex to Present at Biotech Showcase™ 2024
21.12.202312:00EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
20.12.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.12.202307:00GLOBEAddex Shareholders Approve All Resolutions at Extraordinary..
14.12.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14.12.202307:00GLOBEAddex Creates Treasury Shares
08.12.202320:11EDGAR2Form SC 13D/A - General statement of acquisition of..
30.11.202322:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
30.11.202306:15EDGAR2Form EFFECT - Notice of Effectiveness
29.11.202322:00EDGAR2Form SC 13D/A - General statement of acquisition of..
29.11.202312:27EDGAR2Form POS AM - Post-Effective amendments for registration..
29.11.202312:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29.11.202307:00GLOBEAddex Reports Q3 2023 Financial Results and Provides..
28.11.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28.11.202307:00GLOBEAddex Convenes Extraordinary General Meeting
23.11.202307:00GLOBEAddex Therapeutics to Release Third Quarter 2023 Financial..
14.11.202307:00GLOBEAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment..
08.11.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08.11.202307:00GLOBEAddex Regains Nasdaq Listing Compliance
02.11.202307:00GLOBEAddex Announces Participation in the Bio-Europe 2023..
23.10.202312:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20.10.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.10.202307:00GLOBEAddex Completes ADS Ratio Change
06.10.202322:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06.10.202322:00GLOBEAddex Announces Plan to Implement ADS Ratio Change
20.9.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20.9.202307:00GLOBEAddex mGlu2 NAM Cognition Program Receives €4 Million Grant
06.9.202307:00GLOBEAddex Announces Participation in the H.C. Wainwright 25th..
05.9.202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.9.202312:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.9.202307:00GLOBEAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout..
04.9.202307:00GLOBEAddex’s Dipraglurant Development in Post-Stroke Recovery..
11.8.202322:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10.8.202322:00EDGAR2Form POS AM - Post-Effective amendments for registration..
10.8.202312:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10.8.202307:00GLOBEAddex Reports 2023 Half Year and Second Quarter Financial..
04.8.202307:00GLOBEAddex Therapeutics to Release Half-Year 2023 Financial..
03.8.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03.8.202307:00GLOBEAddex GABAB Positive Allosteric Modulator Program to Receive..
24.7.202312:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Kürzlich von Ihnen besucht

NASDAQ
ADXN
Addex Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten